AO "Organika" ORD
MMOEX:ORGN20,000.00
RUB
+5,000.00
(+33.33%)
ISIN
RU0009177356
Return %
Stock
S&P 500
1Y
0.00
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Andrey Petrovich Lyangus
- Sector
- Health technology
- Industry
- Pharmaceuticals: generic
- Address
- Novokuznetsk Russian Federation
- Website
- organica-nk.ru
- Similar Companies
- Business
- AO Organika is a Russian pharmaceutical manufacturing company that specializes in the development, synthesis, and commercial production of active pharmaceutical ingredients (APIs) and finished generic pharmaceutical products. Founded in 1962 and headquartered in Novokuznetsk, Kemerovo Oblast, Russian Federation, the enterprise operates integrated chemical-synthesizing and pharmaceutical manufacturing facilities supplying hospital networks, state healthcare programs, and retail pharmacy chains across the Russian Federation and neighboring member states of the Eurasian Economic Union (EAEU) and Commonwealth of Independent States (CIS). The company manufactures and markets a diverse portfolio of pharmaceuticals across multiple core therapeutic categories and delivery formats, comprising: central nervous system, psychiatric, and neurological medications, including anxiolytics, tranquilizers, sedatives, neuroleptics, antidepressants, and anticonvulsants such as phenazepam, tofisopam, clonazepam, chlorprothixene, and amitriptyline; cardiovascular therapies, including antihypertensives, beta-blockers, and ACE inhibitors such as enalapril, amlodipine, and bisoprolol; analgesics, antipyretics, and non-steroidal anti-inflammatory drugs (NSAIDs), including metamizole sodium, ketorolac, paracetamol, and ibuprofen; gastrointestinal agents, including antispasmodics and antisecretory treatments; antimicrobial and antiviral agents; and active pharmaceutical substances synthesized for captive formulation and commercial wholesale distribution. Finished formulations are produced across various dosage forms, including film-coated and uncoated tablets, hard gelatin capsules, oral powders, and sterile injectable solutions in glass ampoules. In recent operational developments, AO Organika has advanced strategic technical re-equipment and production modernization programs across its solid dosage and sterile liquid manufacturing lines to strengthen compliance with current Good Manufacturing Practice (GMP) standards. In alignment with national pharmaceutical import substitution frameworks, the company has expanded domestic synthesis of critical active pharmaceutical ingredients and broadened its generic portfolio in essential psychiatric, neurological, and cardiovascular segments. Additionally, the company has upgraded its automated packaging lines to maintain compliance with federal end-to-end digital track-and-trace serialization systems, optimized regional supply agreements with major pharmaceutical distributors, and invested in quality assurance laboratory equipment to support increased production capacities.